Sana Biotechnology, Inc. (SANA) Earnings Call Transcripts
Sana Biotechnology, Inc.'s Latest Earnings Call - June 9, 2026
In the second quarter of fiscal year 2026, Sana Biotechnology, Inc. (SANA:US) reported significant advancements in its type 1 diabetes and in vivo CAR-T programs, which could serve as key catalysts for future growth. The company is on track to file an IND and begin a Phase I study for its gene-modified stem cell-derived pancreatic islet therapy this year, with management expressing optimism about achieving a functional cure for type 1 diabetes. Financially, the company ended the quarter with approximately $195 million in cash, providing a runway into mid-2027, although further capital raises may be necessary to support ongoing development efforts.
Reported metrics
| Metric | Value |
|---|---|
| Cash Position | $195 million (positive) |
| Type 1 Diabetes Patients Targeted | 10 million (positive) |
| IND Filing Timeline | 2026 (positive) |
| Phase I Study Size | 12 to 15 patients (neutral) |
| Funding Needs | To be determined (neutral) |
Guidance from management
Management is optimistic about initiating the Phase I study for the type 1 diabetes program in 2026, with a focus on achieving a functional cure. They also indicated that they will need to raise additional capital to support ongoing development efforts.
What analysts pressed on
Analysts expressed concerns regarding the timeline for manufacturing readiness and the potential need for additional funding. There is also caution regarding the safety and efficacy of the in vivo CAR-T therapies as they move into human trials.
Main topics on the call
- Type 1 Diabetes Program Progress — Sana is advancing its gene-modified stem cell-derived pancreatic islet therapy, aiming for a functional cure for type 1 diabetes. CEO Steve Harr stated, "Our goal is to file our IND and begin the Phase I study this year,...
- In Vivo CAR-T Development — The company is preparing to dose patients with its in vivo CAR-T candidate SG293, targeting CD19. Harr expressed confidence, stating, "I think we'll learn if it works or not this year," signaling a pivotal moment for the...
- Financial Position — Sana ended the quarter with approximately $195 million in cash, which CEO Harr noted would support operations into mid-2027. However, he acknowledged the need for further capital raises, stating, "We will need to raise m...
- Manufacturing and Regulatory Challenges — Management highlighted ongoing efforts to finalize nonclinical testing and tech transfer for manufacturing. Harr mentioned, "We have to finish our manufacturing tech transfer," indicating that these are critical gating f...
Read the full Sana Biotechnology, Inc. transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Sana Biotechnology, Inc.
Sana Biotechnology, Inc. (SANA) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 30 calls on record spanning May 12, 2021 to June 9, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 30 Sana Biotechnology, Inc. earnings call transcripts on record, spanning May 12, 2021 to June 9, 2026. Based on this history, Sana Biotechnology, Inc. reports quarterly. The most recent call on file is dated June 9, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- SANA
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 30
- First call
- May 12, 2021
- Most recent
- June 9, 2026
- Reporting cadence
- quarterly